$20 million for clinical innovation at university gifted by Tobias, Lechleiter families
Former Eli Lilly and Co. CEOs Randall Tobias and John Lechleiter, with their wives Deborah and Sarah, respectively, have partnered to commit a combined $20 million gift to create the Tobias-Lechleiter Institute for Clinical Innovation at Indiana University Health.
IU Health is also matching the gift, providing a total of $40 million. The donation was announced recently.
The Lechleiter and Tobias families are each giving an estate gift of $10 million, which together becomes the largest gift received by the IU Health Foundation, the philanthropic arm of Indianapolis-based health system IU Health.
The Tobias-Lechleiter Institute will focus on enrolling more Hoosiers in clinical trials and advancing medical research at IU Health and the IU School of Medicine. The two institutions will share the resources and impact from the gift at the new institute.
“It’s really a gift that’s intended to benefit both organizations, and that’s a huge win for us as we look at what collaboration and partnership looks like across the board,” said Crystal Miller, president of the IU Health Foundation. “It really means for us we can help make people healthier faster.”
Miller said it was rare to receive a major gift from two high-profile former CEOs from the same company and their spouses—all friends who often socialize together.
Tobias was CEO of Indianapolis-based drugmaker Lilly from 1993 through 1998, and Lechleiter, who spent his career at Lilly, was CEO from 2008 through 2016.
“I can’t imagine anybody else we would have teamed up with,” Tobias said.
Tobias said the two families first discussed the gift while relaxing on the porch of his lake house.
The Tobias family was already planning to make a gift, and Randall asked John if he’d like to join, also mentioning the plan for IU Health to match the gift.
“I said, ‘You sort of had me at hello,’” John Lechleiter remembered telling Tobias.
“Both of us, the Tobiases and the Lechleiters, from experience at Lilly, understand the importance of clinical trials,” Lechleiter said. “We want Indiana to be well represented in clinical trials.”
Tobias said the boost in clinical trials and research at IU Health and the IU School of Medicine would have a global impact.
Miller of the IU Health Foundation said the $20 million gift match from IU Health will be used immediately.
“I’ve worked with so many people who have left estate gifts, and they’ve never gotten a chance to see the true impact of their dollars,” she said. “So this is a way that we want to be able to engage with our donors.”
IU Health said the institute will serve as a hub for groundbreaking disease detection and treatment in Indianapolis and across the state. The institute’s work will begin immediately.
The Tobias-Lechleiter Institute for Clinical Innovation has multiple goals. Among the specific aims, the institute wants to increase the number of Hoosiers participating in medical studies to 75,000 patients yearly to provide access to groundbreaking care, medications, and interventions.
Another goal is to enroll 300,000 patients in the Indiana Biobank initiative over the next five years to serve as the foundation for transformative research by understanding genomic risk factors.
In addition, IU Health said the Tobias-Lechleiter Institute will work to provide clinicians and researchers with access to leading-edge resources, to accelerate the speed and impact of medical research, and to help attract and retain top medical talent.
“Thanks to this commitment, our patients will get early access to life-saving treatments, and The Institute for Clinical Innovation will become a destination for leading-edge health care,” IU Health President and CEO Dennis Murphy said in a written statement.
IU Health and the IU School of Medicine have a massive reach involving more than 4.6 million annual care encounters involving more than 1.2 million patients. IU Health said its large patient demographics closely reflect national demographics, making this data valuable to the broader life sciences community.
“We want Indiana to be well represented in clinical trials,” Lechleiter said. “The thing that is particularly appealing about this is the IU Health match. We’ll get this work underway immediately and will be here to watch it be shaped and to grow.”